Abstract:BACKGROUND: During the neonatal stage, the cardiomyocyte undergoes a constellation of molecular, cytoarchitectural, and functional changes known collectively as cardiomyocyte maturation to increase myocardial contractility and cardiac output. Despite the importance of cardiomyocyte maturation, the molecular mechanisms governing this critical process remain largely unexplored. METHODS: We leveraged an in vivo mosaic knockout system to characterize the role of Carm1 , the founding member of protein arginine methyltransferase, in cardiomyocyte maturation. Using a battery of assays, including immunohistochemistry, immuno-electron microscopy imaging, and action potential recording, we assessed the effect of loss of Carm1 function on cardiomyocyte cell growth, myofibril expansion, T-tubule formation, and electrophysiological maturation. Genome-wide transcriptome profiling, H3R17me2a chromatin immunoprecipitation followed by sequencing, and assay for transposase-accessible chromatin with high-throughput sequencing were used to investigate the mechanisms by which CARM1 (coactivator-associated arginine methyltransferase 1) regulates cardiomyocyte maturation. Finally, we interrogated the human syntenic region to the H3R17me2a chromatin immunoprecipitation followed by sequencing peaks for single-nucleotide polymorphisms associated with human heart diseases. RESULTS: We report that mosaic ablation of Carm1 disrupts multiple aspects of cardiomyocyte maturation cell autonomously, leading to reduced cardiomyocyte size and sarcomere thickness, severe loss and disorganization of T tubules, and compromised electrophysiological maturation. Genomics study demonstrates that CARM1 directly activates genes that underlie cardiomyocyte cytoarchitectural and electrophysiological maturation. Moreover, our study reveals significant enrichment of human heart disease–associated single-nucleotide polymorphisms in the human genomic region syntenic to the H3R17me2a chromatin immunoprecipitation followed by sequencing peaks. CONCLUSIONS: This study establishes a critical and multifaceted role for CARM1 in regulating cardiomyocyte maturation and demonstrates that deregulation of CARM1-dependent cardiomyocyte maturation gene expression may contribute to human heart diseases.

The Mechanism of Myocardial Hypertrophy Regulated by the Interaction Between Mhrt and Myocardin.

MiR-466h-5p Induces Expression of Myocardin with Complementary Promoter Sequences

Mir-9 and NFATc3 Regulate Myocardin in Cardiac Hypertrophy

The role and molecular mechanism of epigenetics in cardiac hypertrophy

Mechanosensitive Gene Regulation by Myocardin-Related Transcription Factors is Required for Cardiomyocyte Integrity in Load-Induced Ventricular Hypertrophy.

The role of lncRNAKCNQ1OT1/miR-301b/Tcf7 axis in cardiac hypertrophy

Cardiac Hypertrophy and Dysfunction Induced by Overexpression of Mir-214 in Vivo

Microrna-340-5p Functions Downstream Of Cardiotrophin-1 To Regulate Cardiac Eccentric Hypertrophy And Heart Failure Via Target Gene Dystrophin

Mechanism of Cardiac Hypertrophy Regulates by miR-30e

Integrative analysis of transcriptome, DNA methylome, and chromatin accessibility reveals candidate therapeutic targets in hypertrophic cardiomyopathy

Cooperative Interaction between the Basic Helix-loop-helix Transcription Factor dHAND and Myocyte Enhancer Factor 2C Regulates Myocardial Gene Expression

NFATc4 and Myocardin Synergistically Up-Regulate the Expression of LTCC Α1c in ET-1-induced Cardiomyocyte Hypertrophy.

Mechanism of histone deacetylases in cardiac hypertrophy and its therapeutic inhibitors

Epigenetic Regulation of Cardiomyocyte Maturation by Arginine Methyltransferase CARM1

mir15a/mir16‐1 cluster and its novel targeting molecules negatively regulate cardiac hypertrophy

The lncRNA MIAT regulates CPT-1a mediated cardiac hypertrophy through m6A RNA methylation reading protein Ythdf2

Histone Modifications and miRNA Perturbations Contribute to Transcriptional Dysregulation of Hypertrophy in Obstructive Hypertrophic Cardiomyopathy

MiR-27a-3p/Hoxa10 Axis Regulates Angiotensin II-Induced Cardiomyocyte Hypertrophy by Targeting Kv4.3 Expression

Mechanisms of a novel regulatory light chain-dependent cardiac myosin inhibitor

MicroRNAs target gene and signaling pathway by bioinformatics analysis in the cardiac hypertrophy.

A cardiac fibrosis determinative factor, Meox1, blocks direct reprogramming of cardiac myofibroblasts to cardiomyocyte-like cells